Cellectar Biosciences Inc
NASDAQ:CLRB
Balance Sheet
Balance Sheet Decomposition
Cellectar Biosciences Inc
Cellectar Biosciences Inc
Balance Sheet
Cellectar Biosciences Inc
| Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||
| Cash & Cash Equivalents |
10
|
1
|
9
|
1
|
6
|
5
|
2
|
9
|
4
|
11
|
10
|
13
|
11
|
57
|
36
|
20
|
10
|
23
|
|
| Cash Equivalents |
10
|
1
|
9
|
1
|
6
|
5
|
2
|
9
|
4
|
11
|
10
|
13
|
11
|
57
|
36
|
20
|
10
|
23
|
|
| Other Current Assets |
1
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Total Current Assets |
11
|
1
|
9
|
1
|
6
|
5
|
3
|
10
|
4
|
12
|
10
|
14
|
11
|
58
|
37
|
21
|
10
|
24
|
|
| PP&E Net |
0
|
0
|
0
|
4
|
3
|
3
|
2
|
2
|
2
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
4
|
3
|
3
|
2
|
0
|
2
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
1
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
2
|
2
|
3
|
3
|
0
|
4
|
4
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Goodwill |
0
|
0
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
11
N/A
|
1
-87%
|
9
+507%
|
5
-46%
|
11
+120%
|
11
+9%
|
7
-41%
|
13
+97%
|
8
-43%
|
15
+102%
|
13
-16%
|
15
+17%
|
12
-19%
|
59
+379%
|
37
-37%
|
22
-42%
|
12
-44%
|
25
+111%
|
|
| Liabilities | |||||||||||||||||||
| Accounts Payable |
6
|
5
|
3
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
3
|
4
|
7
|
5
|
|
| Accrued Liabilities |
1
|
2
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
11
|
0
|
0
|
0
|
3
|
5
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
2
|
|
| Total Current Liabilities |
7
|
7
|
17
|
1
|
1
|
1
|
5
|
6
|
6
|
2
|
2
|
2
|
3
|
4
|
4
|
6
|
13
|
9
|
|
| Long-Term Debt |
0
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Total Liabilities |
7
N/A
|
7
0%
|
17
+146%
|
5
-73%
|
1
-77%
|
1
+22%
|
5
+288%
|
7
+31%
|
6
-11%
|
2
-70%
|
2
+19%
|
2
-16%
|
3
+78%
|
4
+21%
|
4
+8%
|
6
+46%
|
13
+121%
|
10
-27%
|
|
| Equity | |||||||||||||||||||
| Common Stock |
10
|
14
|
18
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
1
|
20
|
1
|
1
|
6
|
2
|
|
| Retained Earnings |
43
|
60
|
76
|
24
|
31
|
40
|
51
|
59
|
65
|
71
|
84
|
98
|
112
|
127
|
151
|
180
|
217
|
247
|
|
| Additional Paid In Capital |
37
|
40
|
49
|
24
|
41
|
50
|
53
|
66
|
66
|
83
|
94
|
108
|
120
|
162
|
183
|
194
|
210
|
261
|
|
| Total Equity |
4
N/A
|
6
N/A
|
8
-51%
|
0
N/A
|
9
+7 192%
|
10
+7%
|
2
-83%
|
7
+294%
|
2
-75%
|
14
+721%
|
11
-21%
|
13
+23%
|
9
-32%
|
55
+505%
|
33
-40%
|
16
-53%
|
1
N/A
|
16
N/A
|
|
| Total Liabilities & Equity |
11
N/A
|
1
-87%
|
9
+507%
|
5
-46%
|
11
+120%
|
11
+9%
|
7
-41%
|
13
+97%
|
8
-43%
|
15
+102%
|
13
-16%
|
15
+17%
|
12
-19%
|
59
+379%
|
37
-37%
|
22
-42%
|
12
-44%
|
25
+111%
|
|
| Shares Outstanding | |||||||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|